Compounds to Diagnose and Treat Fatty Liver Disease

Technology #ua12-120

Questions about this technology? Ask a Technology Manager

Download Printable PDF

April Lake
Lisa Augustine
Nathan Cherrington
Professor, Pharmacology & Toxicology
Managed By
Rakhi Gibbons
Asst. Director, Life Sciences (520) 626-6695

Title: Compounds to Diagnose and Treat Fatty Liver Disease

Invention: This invention provides a diagnostic and treatment for non-alcoholic steatohepatitus and other liver diseases.


Background: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease worldwide, with a prevalence of 15%-30% in Western populations. The prevalence increases to 58% in overweight individuals and can be as high as 98% in non-diabetic obese individuals. NAFLD ranges from simple steatosis to nonalcoholic steatohepatitis (NASH) and potentially cirrhosis. Diagnosis for NASH is confirmed when a liver biopsy shows the presence of perilobular inflammation, or the presence of hepatocyte ballooning, Mallory hyaline, and acidophil bodies with or without fibrosis. There are currently no therapies that are effective in the treatment of steatohepatitus and there are limited diagnostic technologies for NASH availability.



  • Diagnosis and treatment of NAFLD
  • Potential benefit for the diagnosis and treatment of other liver diseases



  • Binding specificity to diseased tissues
  • A non-invasive NASH diagnostic
  • Anti-inflammatory agent, which may slow or eliminate liver disease progression